Bayer Weighs Selling Its Vet Unit in Post-Monsanto Revamp

Bayer AG is considering a sale of its animal-health business as it scrutinizes its portfolio in the aftermath of the $63 billion Monsanto Co. acquisition, people familiar with the company’s plans said.Bayer is evaluating animal health as part of a broader review, though a sale isn’t imminent, said the people, who asked not to be named because the appraisal hasn’t been made public. No final decisions have been made, and it’s still possible the German company could decide to keep the business.